BioSpace2d
Atara to Cut Half Its Workforce Following FDA-Related Setbacks
Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...
Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
US FDA puts clinical hold on Atara's trials for cancer cell therapies
Atara Biotherapeutics said on Tuesday the U.S. health regulator has placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket ...
Le Lézard9d
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLOtm (tabelecleucel) and ATA3219
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
Buy Rating for Atara Biotherapeutics Driven by Manufacturing Resolution and Strategic Initiatives
Analyst John Newman of Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report), reducing the price target ...
Stocktwits on MSN14d
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip
Atara Biotherapeutics Inc. shares tumbled over 35% on Thursday afternoon, reaching their lowest intraday levels since mid-October. The sharp decline followed the announcement that the U.S. Food and ...
Atara Shares Sink After FDA Stalls Cancer Treatment
Atara Biotherapeutics shares plunged after the FDA rejected its application to bring a blood cancer treatment to market. Shares of the biotechnology company were recently down 46.5% to $7.04. The ...
US FDA declines to approve Atara Biotherapeutics' cancer therapy
The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' therapy to treat patients with a rare cancer that develops after organ or stem cell transplants, sending ...
Le Lézard14d
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...